DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20222872
Published: 2022-10-28

Spectrum of SARSCOV2 infection with the efficacy of Covaxin and Covishield vaccines during third wave of COVID-19 pandemic: an experience of a densest state of India

Rajib Saha

Abstract


Background: Study was conducted to assess the trend or characteristic of SARSCOV2 infection during 3rd wave of pandemic and to compare the efficacy of Covaxin and Covishield Vaccines.

Methods: This descriptive cross-sectional study was conducted with a mixed-method approach (Explanatory sequential mixed method) among the SARSCOV2 infected patients of West Bengal, India on the month of January 2022. In quantitative analysis 277 SARSCOV2 infected patients who were detected as COVID positive within January, were selected randomly from the secondary data source (collected by 20 general practitioners). In qualitative analysis, 11 patients from different categories were interviewed in-depth over the telephone to explain the quantitative data. Bivariate analysis (Mann Whitney U or Kruskal Wallis test) was used as per applicability. Kaplan Meir plot compared the efficacy of Covaxin and Covishield vaccines.  

Results: Most commonly presented symptom were low-grade fever (78.7%), a mild cough (41.9%), mild cold (62.4%), sore throat (41.9%), body ache (47.3%), and headache (33.2%). Few patients had experienced breathing difficulty (1.4%) and hospitalization (1.1%). Mann Whitney U test significantly (p<0.001) justified that Covaxin receivers have infected in late (median 161 days) comparison to other vaccines receivers (Covishield and Sputnik V median 129 days and 115 days respectively). This finding was also demonstrated in Kaplan Meir Plot.

Conclusions: During the 3rd wave of the pandemic, SARSCOV2 infected patients commonly presented with milder symptoms, minimal hospitalization and without any case fatality. Delaying of infection has been observed more among Covaxin receivers compared to others.


Keywords


3rd wave, Covaxin, COVID-19 pandemic, Covishield, Mixed method study

Full Text:

PDF

References


Andrews MA, Arcekal B, Rajesh KR, Krishna J, Suryakala R, Krishnan B et al. First confirmed case of COVID-19 infection in India: A case report. Indian J Med Res. 2020;151:490-2.

Ministry of Health and Family Welfare Home. Available at: https://www.mohfw.gov.in/. Accessed on 20 September 2022.

Ranjan R, Sharma A, Verma MK. Characterization of the second wave of COVID-19 in India. medRxiv. 2021.

India COVID: 27,369,093 Cases and 315,263 Deaths-Worldometer. Available at: https://www.worldometers.info/coronavirus/country/india/. Accessed on 20 September 2022.

West Bengal Population. Available at: https://www.populationu.com/in/west-bengal-population. Accessed on 20 September 2022.

Ghosh D, Sarkar A, Chouhan D. COVID-19 second wave: District level study of concentration of confirmed cases and fatality in India. Environmental Challenges. 2021;5:100221.

Kumar G, Mukherjee A, Sharma RK, Menon GR, Sahu D, Wig N et al. National Clinical Registry for COVID-19 Team. Clinical profile of hospitalized COVID-19 patients in first and second wave of the pandemic: Insights from an Indian registry based observational study. Indian J Med Res 2021;153:(5 and 6):619-28.

Covid-19 Coronavirus pandemic. Available at: https://www.worldometers.info/coronavirus/. Accessed on 20 September 2022.

Thiruvengadam R, Awasthi A, Medigeshi G, Bhattacharya S, Mani S, Sivasubbu S, et al. Effectiveness of chadox1 ncov-19 vaccine against SARS-COV-2 infection during the Delta (b.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis. 2021;S1473-3099(21)00680-0.

Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-COV-2 vaccine (BBV152): A, double-blind, randomised, controlled phase 3 trial. Lancet. 2021;398(10317):2173-84.

Htun YM, Win TT, Aung A, Latt TZ, Phyo YN, Tun TM et al. Initial presenting symptoms, comorbidities and severity of COVID-19 patients during the second wave of epidemic in Myanmar. Trop Med Heal. 2021;49(1):62.

Mielke N, Johnson S, Bahl A. Fully Vaccinated and Boosted Patients Requiring Hospitalization for COVID-19: an Observational Cohort Analysis. medRxiv. 2022.

Vekaria B, Overton C, Wiśniowski A, Ahmad S, Aparicio-Castro A, Curran-Sebastian J et al. Hospital length of stay for COVID-19 patients: Data-driven methods for forward planning. BMC Infect Dis. 2021; 21(1).

Rees E, Nightingale E, Jafari Y, Waterlow N, Clifford S, Pearson C et al. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med. 2020;18(1):e270.

Soriano V, Ganado-Pinilla P, Sanchez-Santos M, Gómez-Gallego F, Barreiro P, De Mendoza C et al. Main differences between the first and second waves of covid-19 in Madrid, Spain. Int J Infect Dis. 2021;105:374-6.

Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK et al. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunol Res. 2022;70(3):289-315.